Canada (CA)

acellular bioactivity of sol-gel derived borate glass-polycaprolactone electrospun scaffolds (2016) Lepry WC, Smith S, Liverani L, Boccaccini AR, Nazhat SN Journal article A description of methods for deriving air pollution land use regression model predictor variables from remote sensing data in Ulaanbaatar, Mongolia (2016) Yuchi W, Knudby AJ, Cowper J, Gombojav E, Amram O, Walker B, Allen RW Journal article, Original article Socio-economic deprivation: a significant determinant affecting stage of oral cancer diagnosis and survival (2016) Auluck A, Walker B, Hislop G, Lear SA, Schuurman N, Rosin M Journal article, Original article Solution-based intramolecular singlet fission in cross-conjugated pentacene dimers (2016) Zirzlmeier J, Casillas R, Reddy R, Coto PB, Lehnherr D, Chernick E, Papadopoulos I, et al. Journal article Unexpected Michael Additions on the Way to 2.3,8.9-Dibenzanthanthrenes with Interesting Structural Properties (2016) Reus C, Lechner M, Schulze M, Lungerich D, Diner C, Gruber M, Stryker JM, et al. Journal article Insights into the pore structure of KIT-6 and SBA-15 ordered mesoporous silica - recent advances by combining physical adsorption with mercury porosimetry. (2016) Guillet-Nicolas R, Ahmad R, Cychosz KA, Kleitz F, Thommes M Journal article, Original article Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials (2016) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials (2016) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS (2016) Gladman DD, Kavanaugh A, Adebajo AO, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials (2016) Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution